Navigation Links
AAPS national biotechnology conference to highlight breakthrough cancer treatments
Date:5/12/2011

ARLINGTON, VA (May 3, 2011) Cancer studies from Mercer University (Ga.) headline groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). The conference takes place Monday, May 16 -Wednesday, May 18 at the Hilton San Francisco Union Square.

Developing an Oral Vaccine for Cervical Cancer

Cervical cancer is the second most common cancer among women in the world . Two preventative vaccines are currently available, but are expensive, require complex storage, and trained personnel to administer injections. A team at Mercer is seeking to change that by developing a nanoparticle based Human Papillomavirus (HPV) oral vaccine.

"The purpose of our study was to develop and test inexpensive HPV virus-like particulate vaccine formulations that can be administered orally much like a tablet or capsule," said Martin D'Souza, Ph.D., director of graduate programs and co-director of the Center for Drug Delivery and Research at Mercer. "If this technique is successful, vaccinations could be conducted in masses rather inexpensively and without the use of needles."

This research is currently in the formulation development phase and is being tested on an animal model. It is hoped that the study will help reduce the price of vaccine development for cervical cancer, helping make it more available to patients in poorer countries.

Promise Held for a Novel Combination Prostate Cancer Vaccine

Prostate cancer is the second-most common cancer among American men . The research team working on the HPV vaccine is also working on a prostate cancer vaccine that would be a combination of transdermal and oral administration.

"By using this vaccine we can assist the body's defenses to fight off the cancer," said D'Souza. "The vaccine also enables the body's immune cells to generate memory against these cancer cells, such that if [they] reemerge at a later stage, which is quite common, then the memory cells mount an immune response and destroy those cells as well."

Current studies in animal models showed that the vaccine delayed tumor growth, and that transdermal followed by oral vaccination produced a better response than transdermal vaccination alone. These particulate vaccines can be designed for individual therapy and aim to be more cost-effective since their production can be scaled up for mass vaccination due to the ease with which they are prepared.


'/>"/>

Contact: Joseph Catapano
catapanoj@aaps.org
703-248-4772
American Association of Pharmaceutical Scientists
Source:Eurekalert

Related biology news :

1. Consumption, carbon emissions and international trade
2. MU professor elected to membership in National Academy of Sciences
3. ASPB members elected to National Academy of Sciences
4. UCSF scientists honored by National Academy of Sciences
5. Louisiana Tech researcher presents on eco-friendly nanotechnology at national conference
6. Life in extreme environments paves the way for international collaboration
7. Engineering students win International Environmental Design Contest
8. Smell and taste experts at international conference -- April 13-17, 2011
9. 18th International Academy of Astronautics Humans in Space Symposium
10. National Biophotonic Sensors and Systems Center announced
11. ASPB member testifies in support of National Science Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 The report ... Equipment, Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by ... growing at a CAGR of 29.63% between 2017 and 2022. ... ... Logo ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
Breaking Biology Technology: